Phase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment
ISRCTN | ISRCTN37494643 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN37494643 |
ClinicalTrials.gov number | NCT00058201 |
Secondary identifying numbers | ESPAC-3 |
- Submission date
- 01/07/2001
- Registration date
- 01/07/2001
- Last edited
- 28/10/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Scientific title | Phase III adjuvant trial in pancreatic cancer comparing 5-Fluorouracil (5FU) and D-L-folinic acid versus gemcitabine versus no adjuvant treatment |
Study acronym | ESPAC-3 |
Study objectives | Not provided at time of registration Please note that as of 03/09/09 the ethics and primary outcomes of this trial were updated. The end date of this trial was also extended from 01/12/2005 to 07/05/2008 |
Ethics approval(s) | Added 03/09/09: Received from local medical ethics committee (MREC ref: 99/8/74) |
Health condition(s) or problem(s) studied | Pancreatic cancer |
Intervention | 1. 5-FU and Folinic Acid: Folinic Acid D-L form: 20 mg/m2 iv bolus injection followed by 5-FU: 425 mg/m2 iv bolus injection given on 5 consecutive days every 28 days for six cycles (24 weeks) 2. Gemcitabine: 1000 mg/m2 given as iv infusion over 30 min once a week for 3 of every 4 weeks for six cycles (24 weeks) 3. No adjuvant |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase III |
Drug / device / biological / vaccine name(s) | 5-Fluorouracil (5FU), D-L-folinic acid, gemcitabine |
Primary outcome measure | Added 03/09/09: 1. Survival at 2 and 5 years 2. Toxicity 3. Quality of life 4. Relapse free survival |
Secondary outcome measures | Not provided at time of registration |
Overall study start date | 03/07/2000 |
Completion date | 07/05/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | Not provided at time of registration |
Key inclusion criteria | 1.1. Patients who have undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas 1.2. Patients with other cancer may be included who have had complete macroscopic resection for unusual malignancies of the pancreas; cancer of the periampullary region; cancer of the intra-pancreatic bile duct; periampullary cancer of uncertain origin 2. Histological confirmation of the primary diagnosis 3. Histological examination of all resection margins 4. No evidence of malignant ascites, liver metastases, spread to other distant abdominal organs, peritoneal metastases, spread to extra-abdominal regions 5. A World Health Organisation (WHO) performance status ≤2 6. Fully recovered from surgery and fit to take part in the trial. Life expectancy of more than 3 months 7. Able to attend for administration of adjuvant therapy 8. Able to attend for long-term follow-up 9. No previous or concurrent malignancy diagnoses 10. No serious medical or psychological condition precluding adjuvant treatment 11. Fully informed written consent given |
Key exclusion criteria | Does not match inclusion criteria |
Date of first enrolment | 03/07/2000 |
Date of final enrolment | 07/05/2008 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Sponsor information
Cancer Research UK (CRUK) (UK)
Charity
Charity
PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom
Phone | +44 (0)207 317 5186 |
---|---|
kate.law@cancer.org.uk | |
Website | http://www.cancer.org.uk |
https://ror.org/054225q67 |
Funders
Funder type
Charity
Cancer Research UK (CRUK) (UK)
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 08/09/2010 | Yes | No | |
Results article | results | 11/07/2012 | Yes | No | |
Results article | results | 01/01/2014 | Yes | No | |
Results article | results | 20/02/2014 | Yes | No | |
Plain English results | 28/10/2021 | No | Yes |
Editorial Notes
28/10/2021: Cancer Research UK plain English results link added.